RA significantly mitigates non-alcoholic fatty liver disease (NAFLD) by repairing mitochondrial damage and modulating the YAP1/TAZ-PPARγ/PGC-1α signaling pathway [40]. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.